Status: Recruiting
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Participants needed: 52
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Tcelltech Inc.Updated: Mar 24, 2026Locations: 4
Eligibility criteria
Subjects must voluntarily participate in the study and sign a written informed c... [+13]
Pregnant or breastfeeding female subjects. [+12]